SGL Investment Advisors Inc. Purchases 39 Shares of Eli Lilly and Company $LLY

SGL Investment Advisors Inc. lifted its position in Eli Lilly and Company (NYSE:LLY) by 9.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 438 shares of the company’s stock after acquiring an additional 39 shares during the period. SGL Investment Advisors Inc.’s holdings in Eli Lilly and Company were worth $341,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. raised its stake in Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the last quarter. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the last quarter. Wellington Management Group LLP raised its stake in Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after buying an additional 81,587 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Eli Lilly and Company by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after buying an additional 682,203 shares during the last quarter. Finally, Nuveen LLC purchased a new position in Eli Lilly and Company during the first quarter valued at $4,613,912,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Leerink Partners reissued a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. Berenberg Bank reissued a “hold” rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Guggenheim reduced their target price on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a report on Wednesday, August 13th. Finally, Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $938.94.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $844.30 on Wednesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The firm has a market capitalization of $799.09 billion, a P/E ratio of 55.18, a PEG ratio of 1.18 and a beta of 0.47. The business has a fifty day moving average of $736.97 and a 200 day moving average of $766.03.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company’s revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. 0.14% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.